Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Hentzien, Maxime; Owen, Andrew; Strub‐Wourgaft, Nathalie; Perez-Casas, Carmen; Trøseid, Marius; Calmy, Alexandra

doi:10.3389/fmicb.2022.998287

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such approaches should be tested in adequately powered clinical trials in the target population of immunocompromised patients. 66 There are multiple antiviral agents in various stages of development. These including an oral version of remdesivir which could be particularly useful for people who cannot take nirmatrelvir/ritonavir due to drug interactions and pegylated interferon lambda.…”

Section: Prevention Of Infectionsmentioning

confidence: 99%

Vaccines and therapeutics for immunocompromised patients with COVID-19

Shoham¹,

Batista²,

Amor³

et al. 2023

eClinicalMedicine

Self Cite

View full text Add to dashboard Cite

Section: Prevention Of Infectionsmentioning

confidence: 99%

Vaccines and therapeutics for immunocompromised patients with COVID-19

Shoham¹,

Batista²,

Amor³

et al. 2023

eClinicalMedicine

Self Cite

View full text Add to dashboard Cite

“…Combinations of anti-infective agents have a number of explicit advantages, including increased efficacy in comparison to monotherapies and mitigation of the rate at which resistance emerges. The utilisation of antiviral drug combinations for treatment and prevention of COVID-19 has already been proposed [15,16], but the speed at which antiviral development was needed complicated the rate at which they could be assessed. In broad terms, drug combinations can be segregated into three categories: (1) combination of two or more antiviral drugs, (2) combination of an antiviral drug with a pharmacoenhancer, or (3) combination between antiviral(s) and disease modifying agents.…”

Section: Introductionmentioning

confidence: 99%

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters

Gallardo-Toledo,

Neary,

Sharp

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

Pibrentasvir (PIB) has been demonstrated to block exonuclease activity of the SARS-CoV-2 polymerase, protecting favipiravir (FVP) and remdesivir (RDV) from post-incorporation excision and eliciting antiviral synergy in vitro. The present study investigated the chemoprophylactic efficacy of PIB, FVP, RDV, FVP with PIB, or RDV with PIB dosed intranasally twice a day, using a Syrian golden hamster contact transmission model. Compared to the saline control, viral RNA levels were significantly lower in throat swabs in FVP (day 7), RDV (day 3, 5, 7), and RDV+PIB (day 3, 5) treatment groups. Similarly, findings were evident for nasal turbinate after PIB and RDV treatment, and lungs after PIB, FVP, and FVP+PIB treatment at day 7. Lung viral RNA levels after RDV and RDV+PIB treatment were only detectable in two animals per group, but the overall difference was not statistically significant. In situ examination of the lungs confirmed SARS-CoV-2 infection in all animals, except for one in each of the RDV and RDV+PIB treatment groups, which tested negative in all virus detection approaches. Overall, prevention of transmission was observed in most animals treated with RDV, while other agents reduced the viral load following contact transmission. No benefit of combining FVP or RDV with PIB was observed.

show abstract

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters

Neary,

Gallardo-Toledo,

Sharp

et al. 2024

Viruses

View full text Add to dashboard Cite

Favipiravir (FVP) and remdesivir (RDV) have demonstrable antiviral activity against SARS-CoV-2. Here, the efficacy of FVP, RDV, and FVP with RDV (FVP + RDV) in combination was assessed in Syrian golden hamsters challenged with SARS-CoV- 2 (B.1.1.7) following intraperitoneal administration. At day 4 post infection, viral RNA and viral antigen expression were significantly lower in lungs for all three treatment groups compared to the sham treatment. Similarly, viral titres in the lungs were lower in all treatment groups compared to the sham treatment. The FVP + RDV combination was the only treatment group where viral RNA in nasal turbinate and lung, virus titres in lung, and viral antigen expression (lung) were all lower than those for the sham treatment group. Moreover, lower viral titre values were observed in the FVP + RDV group compared to other treatment groups, albeit only significantly lower in comparison to those in the RDV-only-treated group. Further assessment of the potential utility of FVP in combination with RDV may be warranted. Future studies should also consider whether the combination of these two drugs may reduce the speed at which drug resistance mutations are selected.

show abstract

Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Abstract: Rethinking treatment paradigms for the deployment of SARS-CoVantiviral drugs on the shifting landscape of new variants.

Cited by 3 publications

References 37 publications

Vaccines and therapeutics for immunocompromised patients with COVID-19

Vaccines and therapeutics for immunocompromised patients with COVID-19

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters

Contact Info

Product

Resources

About